Use of a Catalytic Chiral Leaving Group for Asymmetric Substitutions at sp<sup>3</sup>
-Hybridized Carbon Atoms: Kinetic Resolution of β-Amino Alcohols by <i>p</i>
-Methoxybenzylation
catalytic strategy was developed for asymmetric substitution reactions at sp3‐hybridized carbon atoms by using a chiral alkylating agent generated in situ from trichloroacetimidate and a chiral phosphoric acid. The resulting chiral p‐methoxybenzyl phosphate selectively reacts with β‐amino alcohols rather than those without a β‐NH functionality. The use of an electronically and sterically tuned chiral
SUBSTITUIERTE CYCLOHEXANDERIVATE UND IHRE VERWENDUNG IN ARZNEIMITTELN ZUR BEHANDLUNG VON KARDIOVASKULÄREN ERKRANKUNGEN
申请人:Bayer Aktiengesellschaft
公开号:EP1339670A1
公开(公告)日:2003-09-03
Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases
申请人:——
公开号:US20040235830A1
公开(公告)日:2004-11-25
The invention relates to substituted cyclohexane derivates of formula (I), a method for the production thereof and the use thereof in medicaments, particularly for preventing and/or treating cardiovascular diseases, diseases of the urogenital tract and cerebrovascular diseases.
[DE] SUBSTITUIERTE CYCLOHEXANDERIVATE UND IHRE VERWENDUNG IN ARZNEIMITTELN ZUR BEHANDLUNG VON KARDIOVASKULÄREN ERKRANKUNGEN<br/>[EN] SUBSTITUTED CYCLOHEXANE DERIVATES AND THE USE THEREOF IN MEDICAMENTS FOR TREATING CARDIOVASCULAR DISEASES<br/>[FR] DERIVES DE CYCLOHEXANE SUBSTITUES ET LEUR UTILISATION DANS DES MEDICAMENTS SERVANT AU TRAITEMENT DE MALADIES CARDIOVASCULAIRES
申请人:BAYER AG
公开号:WO2002042257A1
公开(公告)日:2002-05-30
Die vorliegende Erfindung betrifft substituierte Cyclohexanderivate der Formel (I), Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln, insbesondere zur Prävention und/oder Behandlung von kardiovaskulären Erkrankungen, Erkrankungen des Urogenitaltraktes und cerebrovaskulären Erkrankungen.